[{"id":"f856673f-5509-490b-a1a0-017a3519e174","acronym":"EPBSCH","url":"https://clinicaltrials.gov/study/NCT05961410","created_at":"2023-07-27T18:09:07.280Z","updated_at":"2025-02-25T15:54:51.323Z","phase":"Phase 2","brief_title":"Eltrombopag for Peripheral Blood Stem Cell Harvest","source_id_and_acronym":"NCT05961410 - EPBSCH","lead_sponsor":"National Taiwan University Hospital","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promacta (eltrombopag)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 08/15/2023","start_date":" 08/15/2023","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-10-18"},{"id":"67d3747a-7f09-4303-93f6-55b4cec91b2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01791101","created_at":"2021-01-18T07:54:58.436Z","updated_at":"2024-07-02T16:36:29.156Z","phase":"Phase 2","brief_title":"Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.","source_id_and_acronym":"NCT01791101","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" IL2RA • CD4 • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["IL2RA • CD4 • FOXP3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promacta (eltrombopag)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 09/16/2013","start_date":" 09/16/2013","primary_txt":" Primary completion: 06/26/2020","primary_completion_date":" 06/26/2020","study_txt":" Completion: 06/26/2020","study_completion_date":" 06/26/2020","last_update_posted":"2021-06-11"},{"id":"a7eca77e-c2d8-4a6d-8970-5110ee75806d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02323178","created_at":"2022-04-24T08:57:08.594Z","updated_at":"2025-02-25T13:11:24.938Z","phase":"Phase 1/2","brief_title":"A Study of Eltrombopag in Patients With CMML and Thrombocytopenia","source_id_and_acronym":"NCT02323178","lead_sponsor":"Groupe Francophone des Myelodysplasies","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promacta (eltrombopag)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 08/07/2014","start_date":" 08/07/2014","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 04/01/2021","study_completion_date":" 04/01/2021","last_update_posted":"2021-04-20"},{"id":"4c488573-4cea-4c69-a6f6-2a6ffffd1ad7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01286675","created_at":"2021-01-18T05:13:16.752Z","updated_at":"2024-07-02T16:37:02.334Z","phase":"Phase 1","brief_title":"Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT","source_id_and_acronym":"NCT01286675","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promacta (eltrombopag)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2019-03-01"}]